The 15 references in paper O. Malkova G., I. Leiderman N., A. Levit L., S. Nitenko P., О. Малкова Г., И. Лейдерман Н., А. Левит Л., С. Нитенко П. (2009) “Расстройства липидного обмена при тяжелом сепсисе: клиническое значение и новые методы коррекции // Lipid Metabolic Disturbances in Severe Sepsis: Clinical Significance and New Methods of Correction” / spz:neicon:reanimatology:557

1
Bell J. G., MacKinlay E. E., Dick J. R. et al. Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukot. Essent. Fatty Acids 2004; 71 (4): 201—204.
(check this in PDF content)
2
Cunnane S. C. Problems with essential fatty acids: time for a new paradigm? Prog. Lipid Res. 2003: 42 (6): 544—568.
(check this in PDF content)
3
Alberts B., Bray D., Hopkin K. et al.Essential Cell Biology. 2nd ed. Garland Science; 2004.
(check this in PDF content)
4
Cerra F. B.Hypermetabolism, organ failure, and metabolic support. Surgery 1987; 101 (1): 1—14.
(check this in PDF content)
5
Bone R. C. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann. Intern. Med. 1996; 125 (8): 680—687.
(check this in PDF content)
6
Bone R. C., Grodzin C. J., Balk R. A.Sepsis: A New hypothesis for pathogenesis of the disease process. Chest 1997; 112 (1): 235—243.
(check this in PDF content)
7
Calder P. C.n-3 fatty acids, inflammation, and immunity-relevance to postsurgical and critically ill patients. Lipids 2004; 39 (12): 1147— 1161.
(check this in PDF content)
8
Штатнов М. К.Парентеральное питание с применением жировых эмульсий, содержащих жирные кислоты со средней длиной молекулы в триглицеридах. Вестн. интенс. терапии 2001; 1: 35—42. (часть 1).
(check this in PDF content)
9
Снеговой А. В.Жировые эмульсии в клинической практике. Вестн. интенс. терапии 2005; 3: 74—78.
(check this in PDF content)
10
Ton M. N., Chang C., Carpentier Y. A., Deckelbaum R. J. In vivoandin vitro properties of an intravenous lipid emulsion containing only medium chain and fish oil triglycerides. Clin. Nutr. 2005; 24 (4): 492—501.
(check this in PDF content)
11
Adolph M.Lipid emulsions in parenteral nutrition — state of the art and future perspectives. Clin Nutr 2001; 20 (Suppl. 4): 11—14.
(check this in PDF content)
12
Grimminger F., Seeger W., Mayer K.Use of n-3 fatty acid containing lipid emulsions in the intensive care unit environment: the clinician's view. Clin. Nutr. 2002; 21 (Suppl.2): 23—29.
(check this in PDF content)
13
Berger M. M., Tappy L., Revelly J. P. et al.Fish oil after abdominal aorta aneurysm surgery. Eur. J. Clin. Nutr. 2008; 62 (9): 1116—1122.
(check this in PDF content)
14
Wichmann M. W., Thul P., Czarnetzki H. D. et al. Evaluation of clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipoplus, MLF 541): Data from a prospective, randomized, multicenter trial. Crit. Care Med. 2007; 35 (3): 700—706.
(check this in PDF content)
15
5th Physicians and Pharmacists Forum. Fish oil — a parenteral perspective. ESPEN 2007. Поступила 22.05.09 63rdPostGraduate Assembly in Anesthesiology (PGA) December, 11—15, New York, USA
(check this in PDF content)